Jazz Pharmaceuticals JAZZ Deferred Finance Costs Noncurrent Net
Deferred Finance Costs Noncurrent Net at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredFinanceCostsNoncurrentNet.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's deferred finance costs noncurrent net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's deferred finance costs noncurrent net?
- Jazz Pharmaceuticals (JAZZ) reported deferred finance costs noncurrent net of $7.1M in Q1 2026.
- How has Jazz Pharmaceuticals's deferred finance costs noncurrent net changed year-over-year?
- Jazz Pharmaceuticals's deferred finance costs noncurrent net decreased by 21.1% year-over-year, from $9M to $7.1M.
- What is the long-term trend for Jazz Pharmaceuticals's deferred finance costs noncurrent net?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's deferred finance costs noncurrent net has grown at a 7.7% compound annual growth rate (CAGR), from $5.24M to $7.6M.
- What does deferred finance costs noncurrent net mean?
- The unamortized portion of long-term debt issuance costs.
- How do you interpret deferred finance costs noncurrent net?
- A decrease indicates ongoing amortization of financing costs, while a significant increase may signal new debt issuance or refinancing activities.
- How does deferred finance costs noncurrent net compare across companies?
- Standard across capital-intensive industries; peers with higher debt loads typically show larger balances.